The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effects of the Serotonin Transporter Gene Promoter Polymorphism onMirtazapine and Paroxetine Efficacy and Adverse Events in Geriatric MajorDepression
Abstract
BACKGROUND: The "long/short"polymorphism (5HTTLPR) in the promoter of the serotonin transporter gene (SLC6A4) has been proposed as a pharmacogenetic marker for antidepressant efficacy. Some but not all studies have found that the short form of 5HTTLPR (S allele) results in decreased efficacy of selective serotonin reuptake inhibitors. OBJECTIVE: To determine if the 5HTTLPR polymorphism influences the efficacy and tolerability of mirtazapine and paroxetine hydrochloride, 2 frequently prescribed antidepressants with differing pharmacologic profiles, in geriatric depression. DESIGN: Double-blind, randomized 8-week study. SETTING: Eighteen academic and private outpatient clinics. PATIENTS: We evaluated 246 cognitively intact patients 65 years or older with major depression. INTERVENTIONS: Antidepressant therapy with 15 to 45 mg/d of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n = 122). MAIN OUTCOME MEASURES: The Hamilton Depression Rating Scale-17 and Geriatric Depression Scale, severity of adverse events and dosing compliance indexes, and discontinuations due to adverse events. Outcome measures were stratified according to 5HTTLPR genotypes. RESULTS: Geriatric Depression Scale scores indicated that S allele carriers treated with paroxetine showed a small impairment in antidepressant response. Among mirtazapine-treated patients, there was little indication that the 5HTTLPR genotype affected antidepressant efficacy. However, the 5HTTLPR polymorphism had a dramatic effect on adverse events. Among paroxetine-treated subjects, S allele carriers experienced more severe adverse events during the course of the study, achieved significantly lower final daily doses, and had more discontinuations at days 14, 21, 28, 42, and 49. Surprisingly, among mirtazapine-treated subjects, S allele carriers had fewer discontinuations due to adverse events, experienced less severe adverse events, and achieved higher final daily doses. CONCLUSIONS: These results support the hypothesis that the S allele of 5HTTLPR at the SLC6A4 locus is associated with a poor outcome after treatment with selective serotonin reuptake inhibitors. However, the major effect was on the tolerability of these drugs rather than efficacy. Results from mirtazapine-treated patients indicate that the effect of this polymorphism on outcome may depend on the mechanism of antidepressant action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Greenberg, B. D., Tolliver, T. J., Huang, S.-J., Li, Q., Bengel, D., & Murphy, D. L. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990205)88:1<83::aid-ajmg15>3.0.co;2-0 · Cited by 533
Heinz, A., Jones, D. W., Mazzanti, C., Goldman, D., Ragan, P., Hommer, D., Linnoila, M., & Weinberger, D. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00171-7 · Cited by 466
Pollock, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00132-9 · Cited by 415
Serotonin transporter gene polymorphism and antidepressant response
Kim, D. K., Lim, S.-W., Lee, S., Sohn, S. E., Kim, S., Hahn, C. G., & Carroll, B. J. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00042 · Cited by 398
(1996) · PubMed · Cited by 328
Dechant, K. L., & Clissold, S. P. (1991) · Drugs · doi:10.2165/00003495-199141020-00007 · Cited by 325
Cited by
Pezawas, L., Meyer-Lindenberg, A., Drabant, E. M., Verchinski, B. A., Munoz, K. E., Kolachana, B. S., Egan, M. F., Mattay, V. S., Hariri, A. R., & Weinberger, D. R. (2005) · Nature Neuroscience · doi:10.1038/nn1463 · Cited by 1,980
“), and s alleles adversely affect outcome of SSRI treatmen”
BackgroundAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Genetics of emotional regulation: the role of the serotonin transporter in neural function
Hariri, A. R., & Holmes, A. (2006) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2006.02.011 · Cited by 669
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
“The finding was confirmed by other authors (Kato and Serretti, 2010; Murphy et al., 2004; Perlis et al., 2003; Popp et al., 2006; Reimherr et al., 2010; Hu et al., 2007), even if negative findings exist as well (Huezo-Diaz et al., 2009; Wilkie et al., 2009).”
MethodResultInfluentialPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Personalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
Naismith, S. L., Norrie, L. M., Mowszowski, L., & Hickie, I. B. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.009 · Cited by 270
Serotonin: A never-ending story
Olivier, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.031 · Cited by 253
Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195
How can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177
Treatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163
TRDB--The Tandem Repeats Database
Gelfand, Y., Rodriguez, A., & Benson, G. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1013 · Cited by 159
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Abdolmaleky, H. M., Nohesara, S., Ghadirivasfi, M., Lambert, A. W., Ahmadkhaniha, H., Ozturk, S., Wong, C. K., Shafa, R., Mostafavi, A., & Thiagalingam, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.007 · Cited by 102
“The short allele of 5-HTT promoter polymorphism has been implicated with a poor response to SSRI treatment as well (Murphy et al., 2004).”
Ignácio, Z. M., Réus, G. Z., Abelaira, H. M., & Quevedo, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.036 · Cited by 65
Herold, N., Uebelhack, K., Franke, L., Amthauer, H., Luedemann, L., Bruhn, H., Felix, R., Uebelhack, R., & Plotkin, M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0429-7 · Cited by 61
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Self-citationPharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6
Metadata
- Authors
- Murphy, G. M., Hollander, S. B., Rodrigues, H. E., Kremer, C., & Schatzberg, A. F.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1163
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2053730389
- Cited by
- 275
- References
- 27
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.